AbbVie Reports Positive Results for ABBV-295 in Phase 1 Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 09 2026
0mins
Should l Buy ABBV?
Source: NASDAQ.COM
- Clinical Trial Results: AbbVie announced positive topline results from the Phase 1 study of ABBV-295, indicating good safety and tolerability, particularly highlighting significant weight loss effects.
- Weight Loss Efficacy: During the 12-13 week treatment period, the ABBV-295 group showed dose-dependent weight changes ranging from -7.75% to -9.79% at week 12, compared to only -0.26% in the placebo group, underscoring ABBV-295's potential in weight management.
- Participant Demographics: The study primarily enrolled male participants (88.3%) with a body mass index (BMI) below 30 kg/m2, providing insights into the target demographic for future marketing strategies.
- Dosing and Frequency: Various doses (2-14 mg) and titration frequencies were tested, with ABBV-295 demonstrating good tolerability across all levels, laying a solid foundation for its clinical application moving forward.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 212.400
Low
223.00
Averages
252.00
High
289.00
Current: 212.400
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Health Care Stocks Decline 1.1% on NYSE
- Healthcare Sector Weakness: The NYSE Health Care Index fell by 1.1% late Friday afternoon, indicating a decline in market confidence towards the healthcare sector, which may influence short-term investor decisions.
- Market Sentiment Deterioration: The drop in healthcare stocks could be linked to overall market sentiment, as increasing uncertainty about economic prospects leads to capital outflows from the healthcare sector, affecting stock performance of related companies.
- Industry Impact Assessment: The decline in the healthcare sector may negatively affect the financing capabilities and future investment plans of related companies, especially in the current economic environment where firms may face higher borrowing costs.
- Investor Focus Shift: As healthcare stocks decline, investors may shift their attention to other sectors with greater growth potential, further shrinking the market share of healthcare stocks and impacting the long-term development of the industry.
See More
3 Dividend Aristocrats Offering Yields to Help Fight Inflation
Economic Concerns: Investors are feeling uncertain as economic issues continue to impact portfolios, with inflation readings expected to show a rise, particularly influenced by higher oil prices.
Dividend Stocks as a Strategy: Amidst inflationary pressures, buying dividend stocks yielding over 3% is suggested as a strategic move for investors, especially those with a history of consistent payouts.
Company Performance: Companies like Amcor and Chevron are highlighted for their reliable dividend growth, with Amcor increasing payouts for 27 consecutive years and Chevron maintaining a strong position in the energy sector.
Healthcare Sector Resilience: AbbVie is noted for its reliable growth and income in healthcare, with a strong revenue performance and continued dividend increases, making it a solid investment choice amidst inflation concerns.
See More
ABBVIE AIMS TO ELIMINATE LOOPHOLES AND ENHANCE ACCOUNTABILITY IN THE 340B PROGRAM
Program Overview: The initiative focuses on closing loopholes and enhancing accountability within a specific program involving 340B.
Goals and Objectives: The primary aim is to strengthen the integrity and effectiveness of the 340B program, ensuring it serves its intended purpose.
See More
Jim Cramer's Charitable Trust Adjusts Portfolio with J&J and BMY Trades
- Exit from Bristol Myers: Jim Cramer's Charitable Trust sold 1,100 shares of Bristol Myers at approximately $58.94, maintaining a small gain of 3.5%, but opted to exit due to concerns over pharmaceutical tariffs and a failed clinical trial, thereby mitigating potential losses.
- Initiation of Johnson & Johnson Position: Concurrently, the Trust initiated a new position in Johnson & Johnson by purchasing 150 shares at roughly $237.65, which will represent about 1% of the portfolio, reflecting confidence in J&J's long-term growth potential, particularly in its innovative medicines and medical products segments.
- Sales Growth at Johnson & Johnson: Johnson & Johnson generated approximately $94 billion in sales in 2025, with about two-thirds from its pharmaceutical division, particularly strong in oncology, where sales are expected to exceed $50 billion annually by 2030, showcasing its competitive edge in the market.
- Legal Risk Mitigation: Johnson & Johnson has adjusted its legal strategy regarding the baby powder lawsuits, moving away from blanket settlements to address cases individually, which has significantly reduced overall legal risks and provided greater upside potential for its stock price.
See More
Analysis of High-Yield Stock Investment Opportunities
- AbbVie Stock Performance: AbbVie shares have declined 10% this year, yet its 3.4% dividend yield is nearly three times the S&P 500 average, indicating strong financial fundamentals and attractiveness, making it a solid hold for long-term investors seeking stable income.
- Novo Nordisk's Investment Potential: Facing competitive pressures, Novo Nordisk anticipates a 13% revenue decline this year, resulting in a 28% drop in share price; however, its 41% operating profit margin suggests robust profitability, presenting a buying opportunity for long-term investors at current undervalued levels.
- Verizon's Dividend Safety: Verizon Communications offers a high dividend yield of 5.8%, with a payout ratio around 50% indicating short-term dividend safety; despite a nearly 20% rise in 2026, its stock remains below five-year levels, enhancing its appeal as a defensive investment.
- Market Environment Impact: Amid geopolitical uncertainties and high valuations, the overall market has struggled, with the S&P 500 down over 3%, yet high-yield stocks like AbbVie, Novo Nordisk, and Verizon provide stable income sources, making them suitable for investors seeking safety in the current market landscape.
See More
AbbVie Continues to Raise Quarterly Dividend Amid Patent Challenges
- Stable Dividend Growth: AbbVie has raised its quarterly dividend every year since becoming independent in 2013, with the latest dividend at $1.73 per share, or $6.92 annually, demonstrating strong cash flow and shareholder returns despite challenges from Humira's patent expiration.
- Sales Driven by New Drugs: Sales from Skyrizi and Rinvoq are projected to reach $50 billion by 2030, having generated $31 billion in 2025, effectively countering the decline in Humira sales and ensuring future profitability for AbbVie.
- Neuroscience Portfolio Growth: AbbVie's neuroscience products, including Vraylar and Botox Therapeutic, have seen low-teens percentage year-over-year growth, supporting the company's financial health despite declines in other areas like oncology and aesthetics treatments.
- Future Dividend Potential: With earnings expected to rise by 45.4% in 2026 and 10.8% in 2027, AbbVie is positioned for larger dividend increases in the future, and while it is still years away from becoming a Dividend King, its growth potential remains significant.
See More
Health Care Stocks Decline 1.1% on NYSE
- Healthcare Sector Weakness: The NYSE Health Care Index fell by 1.1% late Friday afternoon, indicating a decline in market confidence towards the healthcare sector, which may influence short-term investor decisions.
- Market Sentiment Deterioration: The drop in healthcare stocks could be linked to overall market sentiment, as increasing uncertainty about economic prospects leads to capital outflows from the healthcare sector, affecting stock performance of related companies.
- Industry Impact Assessment: The decline in the healthcare sector may negatively affect the financing capabilities and future investment plans of related companies, especially in the current economic environment where firms may face higher borrowing costs.
- Investor Focus Shift: As healthcare stocks decline, investors may shift their attention to other sectors with greater growth potential, further shrinking the market share of healthcare stocks and impacting the long-term development of the industry.
See More
3 Dividend Aristocrats Offering Yields to Help Fight Inflation
Economic Concerns: Investors are feeling uncertain as economic issues continue to impact portfolios, with inflation readings expected to show a rise, particularly influenced by higher oil prices.
Dividend Stocks as a Strategy: Amidst inflationary pressures, buying dividend stocks yielding over 3% is suggested as a strategic move for investors, especially those with a history of consistent payouts.
Company Performance: Companies like Amcor and Chevron are highlighted for their reliable dividend growth, with Amcor increasing payouts for 27 consecutive years and Chevron maintaining a strong position in the energy sector.
Healthcare Sector Resilience: AbbVie is noted for its reliable growth and income in healthcare, with a strong revenue performance and continued dividend increases, making it a solid investment choice amidst inflation concerns.
See More
ABBVIE AIMS TO ELIMINATE LOOPHOLES AND ENHANCE ACCOUNTABILITY IN THE 340B PROGRAM
Program Overview: The initiative focuses on closing loopholes and enhancing accountability within a specific program involving 340B.
Goals and Objectives: The primary aim is to strengthen the integrity and effectiveness of the 340B program, ensuring it serves its intended purpose.
See More
Jim Cramer's Charitable Trust Adjusts Portfolio with J&J and BMY Trades
- Exit from Bristol Myers: Jim Cramer's Charitable Trust sold 1,100 shares of Bristol Myers at approximately $58.94, maintaining a small gain of 3.5%, but opted to exit due to concerns over pharmaceutical tariffs and a failed clinical trial, thereby mitigating potential losses.
- Initiation of Johnson & Johnson Position: Concurrently, the Trust initiated a new position in Johnson & Johnson by purchasing 150 shares at roughly $237.65, which will represent about 1% of the portfolio, reflecting confidence in J&J's long-term growth potential, particularly in its innovative medicines and medical products segments.
- Sales Growth at Johnson & Johnson: Johnson & Johnson generated approximately $94 billion in sales in 2025, with about two-thirds from its pharmaceutical division, particularly strong in oncology, where sales are expected to exceed $50 billion annually by 2030, showcasing its competitive edge in the market.
- Legal Risk Mitigation: Johnson & Johnson has adjusted its legal strategy regarding the baby powder lawsuits, moving away from blanket settlements to address cases individually, which has significantly reduced overall legal risks and provided greater upside potential for its stock price.
See More
Analysis of High-Yield Stock Investment Opportunities
- AbbVie Stock Performance: AbbVie shares have declined 10% this year, yet its 3.4% dividend yield is nearly three times the S&P 500 average, indicating strong financial fundamentals and attractiveness, making it a solid hold for long-term investors seeking stable income.
- Novo Nordisk's Investment Potential: Facing competitive pressures, Novo Nordisk anticipates a 13% revenue decline this year, resulting in a 28% drop in share price; however, its 41% operating profit margin suggests robust profitability, presenting a buying opportunity for long-term investors at current undervalued levels.
- Verizon's Dividend Safety: Verizon Communications offers a high dividend yield of 5.8%, with a payout ratio around 50% indicating short-term dividend safety; despite a nearly 20% rise in 2026, its stock remains below five-year levels, enhancing its appeal as a defensive investment.
- Market Environment Impact: Amid geopolitical uncertainties and high valuations, the overall market has struggled, with the S&P 500 down over 3%, yet high-yield stocks like AbbVie, Novo Nordisk, and Verizon provide stable income sources, making them suitable for investors seeking safety in the current market landscape.
See More
AbbVie Continues to Raise Quarterly Dividend Amid Patent Challenges
- Stable Dividend Growth: AbbVie has raised its quarterly dividend every year since becoming independent in 2013, with the latest dividend at $1.73 per share, or $6.92 annually, demonstrating strong cash flow and shareholder returns despite challenges from Humira's patent expiration.
- Sales Driven by New Drugs: Sales from Skyrizi and Rinvoq are projected to reach $50 billion by 2030, having generated $31 billion in 2025, effectively countering the decline in Humira sales and ensuring future profitability for AbbVie.
- Neuroscience Portfolio Growth: AbbVie's neuroscience products, including Vraylar and Botox Therapeutic, have seen low-teens percentage year-over-year growth, supporting the company's financial health despite declines in other areas like oncology and aesthetics treatments.
- Future Dividend Potential: With earnings expected to rise by 45.4% in 2026 and 10.8% in 2027, AbbVie is positioned for larger dividend increases in the future, and while it is still years away from becoming a Dividend King, its growth potential remains significant.
See More
